The development of radiolabeled molecular imaging agents for diagnosing Alzheimer's disease.
| Project/Area Number |
14570845
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
SHIBA Kazuhiro Kanazawa University, Advanced science research center, Associate Professor, 学際科学実験センター, 助教授 (40143929)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MORI Hirofumi Kanazawa University, Advanced science research center, Professor, 学際科学実験センター, 教授 (90019604)
OGAWA Kazuma Kanazawa University, Advanced science research center, Assistant Professor, 学際科学実験センター, 助手 (30347471)
|
|---|
| Project Period (FY) |
2002 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2004: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 2003: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2002: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
|---|
| Keywords | sigma receptor / iodovesamicol / molecular imaging agent / Alzheimer'z disease |
|---|
| Research Abstract |
We evaluated the potential of the (+)-enantiomer of radioiodinated 2-[4-(4-iodophenyl)piperidino]cyclohexanol ((+)-[^<125>I]-p-iodovesamicol) [(+)-[^<125>I]pIV], radioiodinated at the para position of the 4-phenylpiperidine moiety, as a single photon emission computed tomography (SPECT) ligand for mapping sigma-1 receptor in the central nervous system.
In competitive inhibition studies, (+)-pIV (Ki=1.3nM) had more than 10 times higher affinity to the sigma-1 (σ-1) receptor than (+)-pentazocine (Ki=19.9nM) or haloperidol (Ki=13.5nM) known as sigma ligands. Also, the binding affinity of (+)-pIV to the σ-1 receptor (Ki=1.3nM), was about 16 times higher than the sigma-2 (σ-2) receptor (Ki=20.4nM). (+)-pIV (Ki=1262nM) had a much lower affinity to VAChT than (-)-vesamicol (Ki=13.0nM) or (-)-pIV. (+)-[^<125>I]pIV had low affinity to the dopamine, serotonin, adrenaline and acetylcholine receptors. Furthermore, in a saturation binding study, (+)-[^<125>I]pIV exhibited a Kd of 6.96 nM with a maximum number of binding sites Bmax of 799.3 fmol/mg of protein.
In vivo studies, significant amounts (approximately 3% of the injected dose) of (+)-[^<125>I]pIV accumulated in rat brain and its retention was prolonged. The accumulation of (+)-[^<125>I]pIV in the rat brain was significantly reduced by the co-administration of sigma ligands such as pentazocine or haloperidol. Ex vivo autoradiography of the rat brain at 1 hr following i.v. injection of (+)-[^<125>I]pIV showed high localization in brain areas rich in sigma-1 receptor. Thus, the distribution of (+)-[^<125>I]pIV was thought to bind to sigma-1 receptor in vivo. These results suggest that radioiodinated (+)-pIV may have the potential to image sigma-1 (σ-1) receptor in vivo, at least in animals.
|
Report
(4 results)
Research Products
(9 results)
